Publication | Open Access

A randomized, phase II trial of cetuximab with or without PX-866, an irreversible oral phosphatidylinositol 3-kinase inhibitor, in patients with relapsed or metastatic head and neck squamous cell cancer

Ii TrialMedicinePharmacologyPathologyHead And Neck CancerCancer TreatmentNeck OncologyOncologyRadiation OncologyTreatment ResistanceCancer ResearchMetastatic Head